Takeda Sustainability Profile
Takeda Pharmaceutical Company Limited, commonly known as Takeda, is a leading global biopharmaceutical firm headquartered in Japan. Founded in 1781, Takeda has evolved into a prominent player in the pharmaceutical industry, with a strong presence in regions such as North America, Europe, and Asia. The company focuses on key therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases, offering innovative treatments that address unmet medical needs. Takeda is renowned for its commitment to research and development, with a robust pipeline of biologics and small molecules. Notable achievements include its strategic acquisitions and partnerships that have bolstered its market position, making it one of the largest pharmaceutical companies in the world. With a dedication to patient-centric solutions, Takeda continues to lead in delivering unique therapies that improve health outcomes globally.
DitchCarbon Score
How does Takeda's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Takeda's score of 92 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Takeda's reported carbon emissions
In 2024, Takeda Pharmaceutical Company reported total carbon emissions of approximately 3,096,000,000 kg CO2e. This includes 273,000,000 kg CO2e from Scope 1, 28,000,000 kg CO2e from Scope 2 (market-based), and a significant 2,795,000,000 kg CO2e from Scope 3 emissions. In comparison, their 2023 emissions were about 4,265,000,000 kg CO2e, with Scope 1 at 279,000,000 kg CO2e, Scope 2 at 33,000,000 kg CO2e (market-based), and Scope 3 at 3,953,000,000 kg CO2e. Takeda has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2040. Specifically, they target a 65% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2016 baseline, and a 25% reduction in absolute Scope 3 emissions by 2030 from a 2022 baseline. Long-term goals include a 90% reduction in Scope 1 and 2 emissions by 2035 and a 90% reduction in Scope 3 emissions by 2040. These targets align with the Science Based Targets initiative (SBTi) and reflect Takeda's commitment to sustainable practices within the pharmaceutical industry. The company is also working towards achieving net-zero emissions for Scopes 1 and 2 by 2035, demonstrating a proactive approach to climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Takeda's Industry?
How Carbon Intensive is Takeda's Location?
Takeda's Scope 3 Categories Breakdown
Takeda's Scope 3 emissions, which decreased by 29% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 63% of Scope 3 emissions.
Top Scope 3 Categories
Takeda's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Takeda has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Kubota Pharmaceutical Holdings Co., Ltd.
Frequently Asked Questions
Common questions about Takeda's sustainability data and climate commitments